Thus, it suggests that PAXX may represent a promising novel target for overcoming chemoresistance in OS therapy, and PAXX deficiency has been observed to re-sensitize chemoresistant osteosarcoma cells to doxorubicin and cisplatin [104]. Here, PAXX is linked to osteosarcoma.